Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of Two Silicone Hydrogel Toric Contact Lenses
Axis Orientation Comparison of Two Silicone Hydrogel Toric Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Johns Creek, GA
Comparison of Two Silicone Hydrogel Toric Contact Lenses
Axis Orientation Comparison of Two Silicone Hydrogel Toric Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Johns Creek, GA
Click here to add this to my saved trials
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
Efficacy of Repository Corticotropin Injection in Patients With Severe and Recalcitrant Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
Efficacy of Repository Corticotropin Injection in Patients With Severe and Recalcitrant Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  12/31/1969
Retina Institute of California
mi
from
Arcadia, CA
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 12/31/1969
Retina Institute of California
mi
from
Arcadia, CA
Click here to add this to my saved trials
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume
Status: Enrolling
Updated:  12/31/1969
Bascom Palmer Eye Institute, University of Miami Health System
mi
from
Plantation, FL
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume
Status: Enrolling
Updated: 12/31/1969
Bascom Palmer Eye Institute, University of Miami Health System
mi
from
Plantation, FL
Click here to add this to my saved trials
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Midwest Cornea Associates, LLC
mi
from
Indianapolis, IN
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Midwest Cornea Associates, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Central Maine Eye Care
mi
from
Lewiston, ME
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Central Maine Eye Care
mi
from
Lewiston, ME
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Andover, MA
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Raynham, MA
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Raynham, MA
Click here to add this to my saved trials
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
The Eye Care Group, PC
mi
from
Waterbury, CT
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
The Eye Care Group, PC
mi
from
Waterbury, CT
Click here to add this to my saved trials
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Status: Enrolling
Updated:  12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Status: Enrolling
Updated: 12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Artesia, CA
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Artesia, CA
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Investigational Site
mi
from
Lake Villa, IL
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Investigational Site
mi
from
Lake Villa, IL
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pennington, NJ
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pennington, NJ
Click here to add this to my saved trials
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated:  12/31/1969
Associated Eye Care
mi
from
Stillwater, MN
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated: 12/31/1969
Associated Eye Care
mi
from
Stillwater, MN
Click here to add this to my saved trials
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated:  12/31/1969
Ophthalmic Consultants of Long Island
mi
from
Garden City, NY
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated: 12/31/1969
Ophthalmic Consultants of Long Island
mi
from
Garden City, NY
Click here to add this to my saved trials
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated:  12/31/1969
Carolina Eyecare Physicians, LLC
mi
from
Mount Pleasant, SC
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated: 12/31/1969
Carolina Eyecare Physicians, LLC
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated:  12/31/1969
Slade & Baker Vision Center
mi
from
Houston, TX
Symfony Toric Intraocular Lens Visual Outcomes
Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)
Status: Enrolling
Updated: 12/31/1969
Slade & Baker Vision Center
mi
from
Houston, TX
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Barney's Pharmacy
mi
from
Augusta, GA
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Barney's Pharmacy
mi
from
Augusta, GA
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Barney's Pharmacy
mi
from
Grovetown, GA
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Barney's Pharmacy
mi
from
Grovetown, GA
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Barney's Pharmacy
mi
from
Louisville, GA
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Barney's Pharmacy
mi
from
Louisville, GA
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Hutton Pharmacy
mi
from
Blackwell, OK
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Hutton Pharmacy
mi
from
Blackwell, OK
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Creative Care Pharmacy
mi
from
Edmond, OK
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Creative Care Pharmacy
mi
from
Edmond, OK
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
Mustang Drug
mi
from
Mustang, OK
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
Mustang Drug
mi
from
Mustang, OK
Click here to add this to my saved trials
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated:  12/31/1969
University of Tennessee College of Pharmacy
mi
from
Nashville, TN
Real-time Glaucoma Medication Adherence
Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma
Status: Enrolling
Updated: 12/31/1969
University of Tennessee College of Pharmacy
mi
from
Nashville, TN
Click here to add this to my saved trials
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Brenart Eye Clinic
mi
from
Yorkville, IL
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Brenart Eye Clinic
mi
from
Yorkville, IL
Click here to add this to my saved trials
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
The Eye Institute of Utah
mi
from
Salt Lake City, UT
Dry Eye Disease Study With Brimonidine
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
The Eye Institute of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center
mi
from
Memphis, TN
Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oakland, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Boise, ID
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Boise, ID
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Abilene, TX
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Abilene, TX
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
La Jolla, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Redlands, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Redlands, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Colorado Springs, CO
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Golden, CO
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Golden, CO
Click here to add this to my saved trials